Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

The biosimilars reach the US market as the US insulin space has seen seismic changes in the last few years, with a clamour of ...

Merilog is expected to be available in July 2025, and Sanofi will provide Merilog to patients for $35 or less for a 30-day ...

The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...

Soliqua 100/33 (insulin glargine/lixisenatide) is a prescription drug that’s used to treat type 2 diabetes. Soliqua 100/33 comes as a prefilled single-use pen for injecting the drug under your skin.

that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two versions of its drug — Semglee cost $269 and a generic ...

Lilly/Boehringer Ingelheim's insulin glargine product will be available in a pre-filled pen and cartridges for a reusable pen. The marketing authorisation for the Alliance's insulin glargine ...